Relay Therapeutics

RELAY THERAPEUTICS INC

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Analyst,Works,On,Personal,Computer,Showing,Business,Analytics,Dashboard,With

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AMKR

BCAX

EOLS

RLAY

TWIN

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Relay Therapeutics shares are trading lower by 17.8% during Wednesday&#39;s session. The company priced its $200 million offering.

Why Relay Therapeutics (RLAY) Stock Is Down 17% Today

analyst ratings image

Downgrades

ACET

ANIP

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

Relay Therapeutics Inc

Press Releases

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

Earnings

Health Care

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Barbara Weber, M.D., Elected to ITM Supervisory Board

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Small Cap

Opinion

Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

General

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

Management

Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors

AVAI

AZNCF

BFLY

BNTX

RVMD

TNGX

TREN

Altimmune

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

MeiraGTx Hldgs

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Regulus Therapeutics

Sana Biotechnology

Stoke Therapeutics

Tango Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Tyra Biosciences

Upstream Bio

Valneva

Verve Therapeutics

Xencor

Guggenheim

Wells Fargo

HC Wainwright & Co.

Goldman Sachs

Stifel

Comments

Relay Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell